Current status of maintenance therapy for advanced ovarian cancer.
Even after countered with and responding to maximal surgical and chemotherapy efforts, advanced ovarian cancer usually ultimately recurs. One strategy employed to forestall recurrence is maintenance chemotherapy, an extension of treatment following a complete response to conventional measures. Many agents have been studied and many more are currently under investigation in maintenance regimens. While phase III data suggest that taxane maintenance prolongs progression-free survival, no overall survival benefit has been established. This article reviews the current status of maintenance therapy for advanced ovarian cancer, including phase III evidence and new and upcoming trials.
New York University School of Medicine, Division of Gynecologic Oncology, New York NY, USA.
Joanie Mayer
JM
Hope
Stephanie V
SV
Blank